The Current Ratio as of October 2024 (TTM) for CymaBay Therapeutics, Inc. (CBAY) is 10.96

According to CymaBay Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 10.96. This represents a change of -14.82% compared to the average of 12.87 of the last 4 quarters.

CymaBay Therapeutics, Inc. (CBAY) Historical Current Ratio (quarterly & annually)

How has CBAY Current Ratio performed in the past?

The mean historical Current Ratio of CymaBay Therapeutics, Inc. over the last ten years is 8.69. The current 10.96 Current Ratio has changed 12.51% with respect to the historical average. Over the past ten years (40 quarters), CBAY's Current Ratio was at its highest in in the September 2023 quarter at 22.76. The Current Ratio was at its lowest in in the June 2017 quarter at 1.49.

CymaBay Therapeutics, Inc. (CBAY) Current Ratio by Quarter and Year

Discovering the peaks and valleys of CymaBay Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

CymaBay Therapeutics, Inc. (CBAY) Average Current Ratio

How has CBAY Current Ratio performed in the past?

The current Current Ratio of CymaBay Therapeutics, Inc. (CBAY) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

CymaBay Therapeutics, Inc. (CBAY) Current Ratio vs. Peers

How is CBAY’s Current Ratio compared to its peers?

CymaBay Therapeutics, Inc.’s Current Ratio is greater than Day One Biopharmaceuticals, Inc. (4.09), greater than X4 Pharmaceuticals, Inc. (6.07), greater than Inozyme Pharma, Inc. (9.84), less than Acumen Pharmaceuticals, Inc. (17.37), greater than Mereo BioPharma Group plc (6.07), less than Akero Therapeutics, Inc. (24.89), less than Terns Pharmaceuticals, Inc. (21.02), greater than Madrigal Pharmaceuticals, Inc. (8.72), less than Viking Therapeutics, Inc. (37.69), greater than Biomea Fusion, Inc. (4.62), greater than Stoke Therapeutics, Inc. (6.67), greater than Homology Medicines, Inc. (4.19), greater than Gossamer Bio, Inc. (8.21), less than 89bio, Inc. (13.92), less than Pliant Therapeutics, Inc. (14.47), greater than Arcellx, Inc. (6.01), greater than Kiniksa Pharmaceuticals, Ltd. (3.57), less than Structure Therapeutics Inc. (41.38), less than Karuna Therapeutics, Inc. (19.31), greater than Phathom Pharmaceuticals, Inc. (6.48),

Build a custom stock screener for CymaBay Therapeutics, Inc. (CBAY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CymaBay Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

CymaBay Therapeutics, Inc. (CBAY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like CymaBay Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.